Drug intelligence / Profile preview

Idoform Plus

Development stage: Preclinical
Lead developer: Pfizer
Administration: Oral

Overview

Idoform Plus is a dietary supplement developed by Pfizer. It is being investigated for its potential to reduce the occurrence of gastrointestinal side effects in healthy subjects who are being treated with amoxicillin/clavulanate, an antibiotic combination. The supplement is administered orally once daily.

Brand names: Idoform Plus

Beyond the preview

Go deeper on Idoform Plus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Idoform Plus.

Explore the full profile